Literature DB >> 19827880

Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran.

Nadereh Behtash1, Mojgan Karimi Zarchi, Maryam Deldar.   

Abstract

BACKGROUND: The aim of this study was to investigate the clinical and histopathological characteristics and the pretreatment that might predict prognosis and to evaluate the impact of postoperative adjuvant therapy on the outcomes of patients with early stage cervical carcinoma.
METHODS: A total of 203 patients with stage IB and stage II cervical cancers treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy were reviewed at the Vali-Asr University Hospital from 1995 to 2002. The median follow-up period was 42 months.
RESULTS: The depth of cervical stromal invasion, clinical stage, histology of pure adenocarcinoma and lymph node (LN) status were important histopathological prognostic factors of cervical carcinoma. Patients' prognosis could be stratified into three groups (low, intermediate and high risk), with five-year relapse free survival (RFS) rates of 93.5%, 80.6% and 64.7%, respectively (p=0.002), and overall survival (OS) was 95.3%, 83.1% and 67.2% (p=0.001). Among the patients with pelvic lymph node metastases who were free of parametrial extension, those who received postoperative chemo-radiotherapy had significantly better RFS (p=0.021) and OS (p=0.030) than those who received no adjuvant therapy. Also of the patients without pelvic LN metastases but at a high risk of recurrence, the individuals who received adjuvant radiotherapy had a significantly more favorable RFS (p=0.038 ) and a marginally improved OS (p=0.064).
CONCLUSION: Depth of cervical stromal invasion, clinical stage and histology are independent predictors of outcome on multivariate analysis using a Cox regression model. RFS is significantly improved with radiotherapy in patients who are without pelvic lymph node metastases but who are in a high risk group for recurrence.

Entities:  

Mesh:

Year:  2009        PMID: 19827880

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis.

Authors:  Min Sun Kyung; Hong Bae Kim; Jung Yeob Seoung; In Young Choi; Young Soo Joo; Me Yeon Lee; Jung Bae Kang; Young Han Park
Journal:  Oncol Lett       Date:  2015-03-05       Impact factor: 2.967

2.  Association of Epidermal Growth Factor 61A>G, Survivin -31G>C, and EFNA1 -1732G>A Polymorphisms with Susceptibility to Colorectal Cancer.

Authors:  Fatemeh Asadian; Mohammadamin Ghadyani; Mohamad Hossein Antikchi; Seyed Alireza Dastgheib; Hossein Neamatzadeh; Elnaz Sheikhpour; Sahel Khajehnoori; Seyed Sajjad Tabei
Journal:  J Gastrointest Cancer       Date:  2020-11-12

3.  Evaluation the Presence of SERPINA5 (Exon 3) and FTO rs9939609 Polymorphisms in Papillary Thyroid Cancer Patients.

Authors:  Seyed Mohammad Moshtaghioun; Nasim Fazel-Yazdi; Mohammad Mandegari; Ahmad Shirinzadeh-Dastgiri; Mohammad Vakili; Habib Fazel-Yazdi
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

4.  Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shengwei Kang; Junxiang Wu; Jie Li; Qing Hou; Bin Tang
Journal:  Med Sci Monit       Date:  2022-03-09

5.  Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Susceptibility to Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mojgan Karimi-Zarchi; Hajar Abbasi; Atiyeh Javaheri; Amaneh Hadadan; Bahare Meibodi; Razieh Sadat Tabatabaei; Yaser Ghelmani; Hossein Neamatzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

Review 6.  Proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic: A systematic review and meta-analysis.

Authors:  Mohammadali Jafari; Seyed Alireza Dastgheib; Farzad Ferdosian; Hamid Mirjalili; Hossein Aarafi; Mahmood Noorishadkam; Mahta Mazaheri; Hossein Neamatzadeh
Journal:  Hematol Transfus Cell Ther       Date:  2021-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.